OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Burns on the Evolving Use of ADCs in HER2-mutant NSCLC

March 21st 2023

Timothy Burns, MD, PhD, discusses the evolving use of antibody-drug conjugates in HER2-mutant non–small cell lung cancer.

Dr. Patel on the Background of the SWOG S1801 Trial in Melanoma

March 20th 2023

Sapna Patel, BA, MD, discusses the rationale for evaluating the use of pembrolizumab before and after surgery for patients with advanced melanoma.

Dr. Henick on Further Exploring the Immune Microenvironment in Lung Cancer

March 20th 2023

Brian Henick, MD, discusses the importance of further exploring biomarkers in the immune microenvironment for immunotherapy in patients with lung cancer.

Dr. Randall on the Diagnosis of Mesenchymal Chondrosarcoma

March 20th 2023

R. Lor Randall, MD, FACS, discusses, the importance of correctly diagnosing mesenchymal chondrosarcoma.

Dr. Garon on the Current Landscape of PD-L1 and CTLA-4 Inhibitor Regimens in NSCLC

March 20th 2023

Edward B. Garon, MD, MS, discusses the use of PD-L1 inhibitor and CTLA-4 inhibitor combinations in non–small cell lung cancer.

Dr. Brunner on the Use of CAR T-cell Therapy to Improve Post-ASCT Responses in Multiple Myeloma

March 20th 2023

Matthew Brunner, MD, discusses how the phase 2 BMT CTN 1902 trial of anti-BCMA CAR T-cell therapy will attempt to address an area of unmet need in multiple myeloma.

Drs Edelman and Fleisher on Personalizing and Adapting Treatment Approaches in Clinical Trials

March 17th 2023

Martin Edelman, MD, and Linda Fleisher, PhD, MPH, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

Drs Gerber and Nwachukwu on the Importance of Streamlining Clinical Research in Cancer Care

March 17th 2023

David Gerber, MD, and Chika Nwachukwu, MD, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

Drs El-Khoueiry and Hughes-Halbert on the Importance of a Multidisciplinary Approach in Cancer Care

March 17th 2023

Anthony B. El-Khoueiry, MD, and Chanita Hughes-Halbert, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

Dr. Mitzman on Neoadjuvant Nivolumab Plus Chemotherapy in NSCLC

March 17th 2023

Brian Mitzman, MD, FACS, FCCP, discusses findings from the phase 3 CheckMate 816 trial in patients with resectable non–small cell lung cancer.

Dr. Brunner on the Utilization of Advanced Imaging Modalities in R/R Multiple Myeloma

March 17th 2023

Matthew Brunner, MD, discusses how to best approach the navigation of advanced imaging modalities in relapsed/refractory multiple myeloma.

Dr. Mukherjee on Maintenance Rituximab in MCL

March 17th 2023

Akash Mukherjee, MD, discusses the use of post-transplant maintenance rituximab in patients with mantle cell lymphoma who have received autologous stem cell transplant and considerations for using bendamustine/rituximab or BR plus cytarabine in elderly patients who are unfit for transplant.

Dr. Brown on the Use of PARP Inhibitors in the Upfront and Recurrent Settings in Ovarian Cancer

March 17th 2023

Jubilee Brown, MD, professor, director, gynecologic oncology, Levine Cancer Institute, Atrium Health, discusses benefits associated with PARP inhibitor maintenance therapy in the upfront and recurrent settings of ovarian cancer.

Dr. Wright on the Benefit of Moderate Hypofractionation in Early-Stage Breast Cancer

March 16th 2023

Jean Wright, MD, discusses the benefit of moderate hypofractionation in patients for adjuvant radiotherapy in patients with early-stage breast cancer.

Dr. Cai on Disparities in Access to Care in Breast Cancer

March 16th 2023

Steven Cai, MD, FACS, discusses the ongoing effort to address disparities in breast cancer care, and the importance of improving access to care for underserved patients.

Dr. Muss on the Use of Metronomic Chemotherapy in Metastatic Breast Cancer

March 16th 2023

Hyman B. Muss, MD, discusses the use of metronomic chemotherapy in metastatic breast cancer.

Dr. Fountzilas on Molecular Characterization in mCRC

March 16th 2023

Christos Fountzilas, MD, FACP, discusses findings from a study of molecular characterization in patients with colorectal cancer treated with cetuximab, an EGFR inhibitor, and pembrolizumab, a PD-1 inhibitor.

Dr. Yu on the Use of PARP Inhibitors and Radiopharmaceuticals in Prostate Cancer

March 16th 2023

Evan Y. Yu, MD, discusses new data and continuing conversations regarding the use of PARP inhibitors and targeted radioligand therapies in prostate cancer.

Dr. Carducci on the Ongoing CAPItello-280 Trial in mCRPC

March 16th 2023

Michael A. Carducci, MD, discusses the significance of two ongoing clinical trials in prostate cancer: the phase 3 CAPItello-280 trial (NCT05348577) and phase 3 INDICATE study (EA8191; NCT04423211).

Dr. Epstein-Peterson on Disease Observation and TP53 Mutations in MCL

March 16th 2023

Zachary Epstein-Peterson, MD, discusses important updates in mantle cell lymphoma treatment, including the safety and feasibility of disease observation in patients with indolent MCL and the treatment of patients with TP53-mutated MCL.